CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

78 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
AFLT3MutationPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaMidostaurinLevis, 2017
DFLT3Y842CPredictiveSupportsResistanceAcute Myeloid LeukemiaFLT3/ABL/Aurora Kinase Inhibitor KW-2449Williams et al., 2013
DFLT3Y842CPredictiveSupportsResistanceAcute Myeloid LeukemiaSunitinibWilliams et al., 2013
DFLT3Y842CPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaMidostaurinWilliams et al., 2013
DFLT3F691LPredictiveSupportsResistanceAcute Myeloid LeukemiaLestaurtinibWilliams et al., 2013
DFLT3F691LPredictiveSupportsResistanceAcute Myeloid LeukemiaMidostaurinWilliams et al., 2013
DFLT3Y842CPredictiveSupportsResistanceAcute Myeloid LeukemiaQuizartinibWilliams et al., 2013
DFLT3N841IPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaMidostaurinJiang et al., 2004
DFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
DFLT3D835YPredictiveSupportsSensitivity/ResponseCancerFLT3 Tyrosine Kinase Inhibitor TTT-3002,Midostaurin,Lestaurtinib,CrenolanibNguyen et al., 2017
DFLT3D835YPredictiveDoes Not SupportSensitivity/ResponseCancerPonatinib,AG1295,AGS324,Linifanib,Quizartinib,Sunitinib,Sorafenib,R406,KW2449Nguyen et al., 2017
DFLT3Overexpression AND FLT3LG ExpressionPredictiveDoes Not SupportSensitivity/ResponseCancerCrenolanib,R406,AG1295Nguyen et al., 2017
DFLT3D593delPredictiveSupportsSensitivity/ResponseCancerFLT3 Tyrosine Kinase Inhibitor TTT-3002,Midostaurin,Lestaurtinib,CrenolanibNguyen et al., 2017
BFLT3AmplificationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerSunitinibAl Baghdadi et al., 2020
BFLT3MutationPrognosticDoes Not SupportAcute Myeloid LeukemiaFröhling et al., 2004
BFLT3ITDPrognosticDoes Not SupportAcute Myeloid LeukemiaGale et al., 2008
BFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaSorafenibMan et al., 2012
BFLT3ITDPredictiveSupportsResistanceAcute Myeloid LeukemiaSelumetinibJain et al., 2014
DFLT3D835VPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaCytarabine,SunitinibYee et al., 2004
DFLT3D835VPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaSunitinib,DaunorubicinYee et al., 2004
DFLT3D835YPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
CFLT3D835PrognosticSupportsPoor OutcomeMyelodysplastic SyndromeShih et al., 2004
DFLT3D835IPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
DFLT3D835HPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
DFLT3D835VPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaGilteritinibLee et al., 2017
CFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaSorafenibBaker et al., 2013
DFLT3D835H/YPredictiveSupportsResistanceAcute Myeloid LeukemiaSorafenibBaker et al., 2013
CFLT3D835VPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaSunitinibFiedler et al., 2005
Page 2 of 2
Previous